Dr. Michael A. Gelfand, MD
Neurology (Epilepsy Physician)
3400 Civic Center Boulevard, 2nd Floor, South Pavilion
Philadelphia, PA 19104
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 249
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Epilepsy Physician primary
PA license MD452895 -
Clinical Neurophysiology Physician
PA license MD452895 -
Neurology Physician
PA license MD452895
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Penn Presbyterian Medical Center Philadelphia, PA
- Lancaster General Hospital Lancaster, PA
- Pennsylvania Hospital Philadelphia, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
- Lancaster General Medical Group (586 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 249
- Services billed
- 429
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 104 | 61 |
| Measurement of brain wave activity (eeg), awake and drowsy | 60 | 60 |
| Established patient office or other outpatient visit, 30-39 minutes | 46 | 43 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 36 | 31 |
| Established patient office or other outpatient visit, 40-54 minutes | 20 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Lamotrigine Er (lamotrigine) Other prescribers in Philadelphia, PA | 178 |
| Clobazam | 174 |
| Lamotrigine Other prescribers in Philadelphia, PA | 143 |
| Levetiracetam Other prescribers in Philadelphia, PA | 136 |
| Lacosamide Other prescribers in Philadelphia, PA | 122 |
| Levetiracetam Er (levetiracetam) Other prescribers in Philadelphia, PA | 106 |
| Xcopri (cenobamate) | 97 |
| Clonazepam Other prescribers in Philadelphia, PA | 63 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in Philadelphia, PA | 56 |
| Nayzilam (midazolam) | 53 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 11 payments worth $9,951 in total to this clinician.
| UCB, Inc. | $7,838 |
|---|---|
| Jazz Pharmaceuticals Inc. | $1,893 |
| Sk Life Science, Inc. | $144 |
| Neurelis, Inc. | $77.30 |
| Consulting Fee | $9,731 |
|---|---|
| Food and Beverage | $221 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB, Inc. Feb 7, 2025 | Consulting Fee | $3,500 |
| Jazz Pharmaceuticals Inc. May 28, 2025 | Consulting Fee EPIDIOLEX · NEUROLOGY | $1,893 |
| UCB, Inc. Nov 21, 2025 | Consulting Fee | $1,375 |
| UCB, Inc. Aug 22, 2025 | Consulting Fee | $1,125 |
| UCB, Inc. May 14, 2025 | Consulting Fee | $875 |
| UCB, Inc. Feb 7, 2025 | Consulting Fee | $375 |
| UCB, Inc. Aug 29, 2025 | Consulting Fee | $250 |
| UCB, Inc. May 14, 2025 | Consulting Fee | $225 |
| UCB, Inc. Nov 21, 2025 | Consulting Fee | $113 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $70,647 in research payments for these studies, mostly to the institutions running them.
- A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB SA · Enrolling by invitation · NCT05076617 - A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB SA · Recruiting · NCT05077904 - A Phase 4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Ol…
Jazz Pharmaceuticals Inc. - An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Terminated · NCT04686786 - A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Completed · NCT04244175
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.